Trial Profile
A Phase II Study of TAS 102 in Combination With Ramucirumab in Advanced, Refractory Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 11 Apr 2024
Price :
$35
*
At a glance
- Drugs Ramucirumab (Primary) ; Tipiracil/trifluridine (Primary)
- Indications Adenocarcinoma; Gastric cancer; Oesophageal cancer
- Focus Therapeutic Use
- 04 Apr 2024 Planned End Date changed from 1 Mar 2024 to 1 Jul 2024.
- 14 Feb 2024 Planned End Date changed from 1 Jan 2024 to 1 Mar 2024.
- 22 Jan 2022 Results presented at the 2022 Gastrointestinal Cancers Symposium